APA (7th ed.) Citation

C, C., D, W., Z, G., Q, X., GJ, R., A, M., . . . RS, S. (2008). Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. Journal of medicinal chemistry, 51(23), 7478. https://doi.org/10.1021/jm8006454

Chicago Style (17th ed.) Citation

C, Chen, et al. "Discovery of Sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-releasing Hormone Receptor." Journal of Medicinal Chemistry 51, no. 23 (2008): 7478. https://doi.org/10.1021/jm8006454.

MLA (9th ed.) Citation

C, Chen, et al. "Discovery of Sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-releasing Hormone Receptor." Journal of Medicinal Chemistry, vol. 51, no. 23, 2008, p. 7478, https://doi.org/10.1021/jm8006454.